Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Micafungin Sodium

FDA-approved product (injectable, intravenous), marketed as Micafungin, Micafungin In Sodium Chloride 0.9%, Micafungin Sodium and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Micafungin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Candidiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antimycotics for systemic use
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX05

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Micafungin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Micafungin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

    NCT00106288 · start 2003-01

    Registered record
    Registry ID
    NCT00106288
    Conditions
    Candidiasis
    Interventions
    Micafungin; Liposomal Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-01
    Completion
    2005-12
    Enrolment
    637

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis
    InterventionMicafungin; Liposomal Amphotericin B
    PhasePhase 3
    Registry statusCompleted

  • Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

    NCT00047827 · start 2002-12

    Registered record
    Registry ID
    NCT00047827
    Conditions
    Aspergillosis
    Interventions
    Micafungin; Liposomal Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2002-12
    Completion
    2003-02
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis
    InterventionMicafungin; Liposomal Amphotericin B
    PhasePhase 2
    Registry statusTerminated

  • Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

    NCT00036179 · start 1999-02-27

    Registered record
    Registry ID
    NCT00036179
    Conditions
    Candidiasis
    Interventions
    FK463
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-02-27
    Completion
    2002-01-27
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis
    InterventionFK463
    PhasePhase 2
    Registry statusCompleted

  • Study of FK463 for the Treatment of Invasive Aspergillosis

    NCT00036166 · start 1999-01-29

    Registered record
    Registry ID
    NCT00036166
    Conditions
    Aspergillosis
    Interventions
    FK463
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-01-29
    Completion
    2002-01-31
    Enrolment
    326

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis
    InterventionFK463
    PhasePhase 2
    Registry statusCompleted

  • Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia

    NCT00001790 · start 1998-10

    Registered record
    Registry ID
    NCT00001790
    Conditions
    Fever; Mycoses; Neutropenia
    Interventions
    FK463
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1998-10
    Completion
    2000-09
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFever; Mycoses; Neutropenia
    InterventionFK463
    PhasePhase 1
    Registry statusCompleted